Distinctive expression of CD133 between intraductal papillary neoplasms of the bile duct and bile duct adenocarcinomas

Hepatology Research

Volumn 42, Issue 6, 2012, Pages 574-582

  Ohtsubo, Izuru ^a   Ajiki, Tetsuo ^a   Hori, Yuichi ^a,b   Murakami, Sae ^a   Shimizu, Kazuya ^c   Itoh, Tomoo ^a   Shimizu, Michio ^d   Fukumoto, Takumi ^a   Ku, Yonson ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c Graduate School of Health Sciences   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Bile duct adenocarcinoma; CD133; Intraductal papillary neoplasms of bile duct

Indexed keywords

CD133 ANTIGEN; MUCIN 1; MUCIN 2; MUCIN 5AC;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HILAR BILE DUCT CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 84860695807     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00954.x     Document Type: Article

References (36)

1. Tajima Y, Kuroki T, Fukuda K, Tsuneoka N, Furui J, Kanematsu T. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg 2004; 91: 99-104.
2. Shibahara H, Tamada S, Goto M etal. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol 2004; 28: 327-38.
3. Zen Y, Fujii T, Itatsu K etal. Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol 2006; 19: 1243-54.
4. Zen Y, Fujii T, Itatsu K etal. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006; 44: 1333-43.
5. Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T. Biliary tract cancer treatment: 5, 584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009; 16: 1-7.
6. Hirano S, Kondo S, Tanaka E etal. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci 2010; 17: 455-62.
7. Miyazaki M, Kimura F, Shimizu H etal. One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci 2010; 17: 470-5.
8. Unno M, Katayose Y, Rikiyama T etal. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2010; 17: 463-9.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8.
10. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
11. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
12. Singh SK, Hawkins C, Clarke ID etal. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
13. Ricci-Vitiani L, Lombardi DG, Pilozzi E etal. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-15.
14. Bao S, Wu Q, Sathornsumetee S etal. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-8.
15. Beier D, Hau P, Proescholdt M etal. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-15.
16. Taylor MD, Poppleton H, Fuller C etal. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8: 323-35.
17. Bao S, Wu Q, McLendon RE etal. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
18. Piccirillo SG, Reynolds BA, Zanetti N etal. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444: 761-5.
19. Hori Y, Fukumoto M, Kuroda Y. Enrichment of putative pancreatic progenitor cells from mice by sorting for Prominin1 (CD133) and platelet-derived growth factor receptor β. Stem Cells 2008; 26: 2912-20.
20. Oshima Y, Suzuki A, Kawashimo K etal. Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 2007; 132: 720-32.
21. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008; 8: 48.
22. Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y. CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas 2009; 38: e207-14.
23. Yoshikawa S, Zen Y, Fujii T etal. Characterization of CD133+ parenchymal cells in the liver: histology and culture. World J Gastroenterol 2009; 15: 4896-906.
24. Shimada M, Sugimoto K, Iwahashi S etal. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 2010; 45: 896-902.
25. Smith LM, Nesterova A, Ryan MC etal. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008; 99: 100-9.
26. Ohtsuka M, Kimura F, Shimizu H etal. Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion. Am J Surg Pathol 2011; 35: 512-21.
27. Sobin LH, Gospodarowicz M, Wittekind C. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours, 7th edn. New York: Wiley, 2010.
28. Furukawa T, Klöppel G, Volkan Adsay N etal. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447: 794-9.
29. Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 2002; 9: 328-41.
30. Hidalgo E, Asthana S, Nishio H etal. Surgery for hilar cholangiocarcinoma: the Leeds experience. Eur J Surg Oncol 2008; 34: 787-94.
31. Theise ND, Saxena R, Portmann BC etal. The canals of Hering and hepatic stem cells in humans. Hepatology 1999; 30: 1425-33.
32. Nakanuma Y, Sasaki M, Sato Y, Ren X, Ikeda H, Harada K. Multistep carcinogenesis of perihilar cholangiocarcinoma arosing in the intrahepatic large bile ducts. World J Hepatol 2009; 1: 35-42.
33. Zen Y, Aishima S, Ajioka Y etal. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. Pathol Int 2005; 55: 180-8.
34. Zen Y, Sasaki M, Fujii T etal. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct - an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 2006; 44: 350-8.
35. INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol 2008; 215: 175-83.
36. Schmitz KJ, Lang H, Wohlschlager J etal. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch 2007; 450: 135-41.